These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17127701

  • 1. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
    Koiwa F, Kakuta T, Tanaka R, Yumita S.
    Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [Abstract] [Full Text] [Related]

  • 3. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A.
    Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Nephron Clin Pract; 2006 Jun; 102(1):c1-7. PubMed ID: 16166800
    [Abstract] [Full Text] [Related]

  • 5. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism.
    Wada A, Sugihara M, Sugimura K, Kuroda H.
    Radiat Med; 1999 Jun; 17(4):275-82. PubMed ID: 10510900
    [Abstract] [Full Text] [Related]

  • 6. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
    Tanaka R, Kakuta T, Fujisaki T, Tanaka S, Sakai H, Kurokawa K, Saito A.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
    [Abstract] [Full Text] [Related]

  • 7. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
    Kuzdak K, Rybińska A, Białas M.
    Endokrynol Pol; 2005 Jun; 56(6):891-6. PubMed ID: 16821207
    [Abstract] [Full Text] [Related]

  • 8. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism.
    de Barros Gueiros JE, Chammas MC, Gerhard R, da Silva Dias Boilesen CF, de Oliveira IR, Moysés RM, Jorgetti V.
    Nephrol Dial Transplant; 2004 Mar; 19(3):657-63. PubMed ID: 14767023
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
    Nakamura M, Fuchinoue S, Teraoka S.
    Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
    [Abstract] [Full Text] [Related]

  • 10. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A.
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
    [Abstract] [Full Text] [Related]

  • 11. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
    Tanaka M, Itoh K, Matsushita K, Ogawa A, Hirayama H, Tsunoda N, Yoshizumi K, Naruse M, Nonoguchi H, Tomita K.
    Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
    [Abstract] [Full Text] [Related]

  • 12. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism.
    Stratigis S, Stylianou K, Mamalaki E, Perakis K, Vardaki E, Tzenakis N, Katsipi I, Papavasiliou S, Yarmenitis S, Kyriazis J, Daphnis E.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):542-8. PubMed ID: 18331604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.
    Douthat WG, Orozco SE, Maino P, Cardozo G, de Arteaga J, de la Fuente J, Chiurchiu CR, Massari PU.
    Transpl Int; 2007 Dec; 20(12):1031-5. PubMed ID: 17883371
    [Abstract] [Full Text] [Related]

  • 15. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism.
    Matsuoka S, Tominaga Y, Sato T, Uno N, Hiramitu T, Goto N, Nagasaka T, Uchida K.
    Ther Apher Dial; 2008 Oct; 12(5):391-5. PubMed ID: 18937723
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism.
    Chen HH, Lu KC, Lin CJ, Wu CJ.
    Nephron Clin Pract; 2011 Oct; 117(2):c120-6. PubMed ID: 20693813
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
    Onoda N, Kashiwagi T, Nakamura T, Niitsu Y, Omata M, Kurihara S.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
    [Abstract] [Full Text] [Related]

  • 20. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
    Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N, Katayama A, Haba T, Kazuharu Uchida (Yagoto PTx Forum).
    Ther Apher Dial; 2007 Aug; 11(4):266-73. PubMed ID: 17661832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.